Attana announced that it has completed a Medical Device listing of Attana Ce 250 and a facility registratition of Attana, with the U.S. Food and Drug Administration (FDA). The facility registration and listing of Attana Cell 250 as a Class I device (510(k) exempt) are the first regulatory requirements for marketing Attanas instruments towards the clinical diagnostics market. In 2021, Attana intends to complement these by filing for an FDA approval of at least one complementary assay as a Class II device, subject to 510(k) clearance. Simultaneous to these efforts, Attana will evaluate the possibility of completing a similar regulatory process with the European Medicines Agency (EMA).